Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Shares Outstanding (Weighted Average) (2016 - 2025)

Plus Therapeutics has reported Shares Outstanding (Weighted Average) over the past 16 years, most recently at $77.8 million for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 1071.71% to $77.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $77.8 million through Dec 2025, up 1071.71% year-over-year, with the annual reading at $77.8 million for FY2025, 1071.71% up from the prior year.
  • Shares Outstanding (Weighted Average) was $77.8 million for Q4 2025 at Plus Therapeutics, down from $107.4 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $134.7 million in Q1 2025 and troughed at $1.5 million in Q2 2022.
  • The 5-year median for Shares Outstanding (Weighted Average) is $4.9 million (2024), against an average of $20.9 million.
  • Year-over-year, Shares Outstanding (Weighted Average) tumbled 85.52% in 2022 and then skyrocketed 3016.96% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $12.1 million in 2021, then tumbled by 85.52% to $1.8 million in 2022, then surged by 79.45% to $3.1 million in 2023, then soared by 111.41% to $6.6 million in 2024, then soared by 1071.71% to $77.8 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Shares Outstanding (Weighted Average) are $77.8 million (Q4 2025), $107.4 million (Q3 2025), and $24.4 million (Q2 2025).